| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 3,210 | 4,640 | 4,120 | 2,700 | 4,020 |
| Sales Growth | -30.82% | +12.62% | +52.59% | -32.84% | -1.71% |
| Net Income | -18,030 | -20,700 | -22,780 | -25,140 | -27,110 |
| Net Income Growth | +12.90% | +9.13% | +9.39% | +7.27% | -23.90% |
Eiger Biopharma (EIGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.